Furthermore, the first pharmacoepigenetic studies performed with MT treatments based on a multifactorial strategy demonstrate that SIRT2, APOE, and CYPD6 are genes that cooperate in the efficacy and safety of anti-AD treatments [191]. Here, APOE is linked to Alzheimer disease.